You are here: Industry Insights > Aeterna Zentaris

News List

Aeterna Zentaris Starts Preclinical Development of Macimorelin as a Potential Treatment for ALS americanpharmaceuticalreview
May 18, 2021
Aeterna Zentaris Inc. has announced the commencement of the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease).
Aeterna Zentaris signs agreement to evaluate oral Covid-19 vaccine pharmaceutical-technology
February 04, 2021
Aeterna Zentaris has signed an exclusive option agreement with the Julius-Maximilians-University Wuerzburg, Germany, to analyse the latter’s preclinical potential Covid-19 vaccine.
Aeterna Zentaris Announces Strategic Review and Engagement of Financial Advisor firstwordpharma
March 13, 2019
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) announced today that its board of directors has formed a special committee of independent directors (the “Special Committee”) to review strategic options available to Aeterna Zentaris.
Aeterna Zentaris Announces ZoptEC Phase 3 Clinical Study of Zoptrex Misses Primary Endpoint americanpharmaceuticalreview
May 02, 2017
Aeterna Zentaris announced the ZoptEC Phase 3 clinical study of Zoptrex in women with locally advanced.
Aeterna Zentaris Intends to File NDA with Respect to Macrilen in Third Quarter of 2017 drugs.com
April 06, 2017
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”) today announced that, following its meeting with the U.S. Food and Drug Administration (the “FDA” or the “Agency”) on March 29, 2017.
Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen™ americanpharmaceuticalreview
February 15, 2017
Eli Lilly and Company and Incyte Corporation announced that the European Commission has granted marketing authorization for Olumiant® (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthr
Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen drugs.com
February 14, 2017
Aeterna Zentaris Inc. announced it concluded that Macrilen™ demonstrated performance supportive of achieving registration with the U.S. Food and Drug Administration.